Please join us for a special series of online seminars for people affected by hereditary breast and ovarian cancer.
Please join us for our next online seminar for people affected by hereditary breast and ovarian cancer.
May 3, 2016
Dr. Charles E. Geyer, Professor of Medicine and Harrigan, Haw, Luck Families Chair in Cancer Research at the Virginia Commonwealth University, Massey Cancer Center describes the OlympiA trial. OlympiA is the first clinical trial for people with a BRCA1 or BRCA2 mutation who have been recently diagnosed with stage 2 or stage 3 breast cancer. The study will evaluate whether the PARP inhibitor olaparib is safe and improves outcomes.